Unlocking the Value of Biosimilar Therapies in IBD

Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases including inflammatory bowel disease (IBD). Biosimilars are molecules highly similar to approved biologic medicines that have been developed to mitigate the high costs of biologics. Despite the fact that these therapies are tested to ensure non-inferiority to originator products, questions about appropriate use of biosiilars in IBD remain among clinicians and patients alike.

In this CME Outfitters webcast, expert faculty will focus on identifying key terminology related to biosimilar products, assessing evidence regarding the efficacy and safety of biosimilars in IBD, and improving patient-provider communication patterns on the topic of biosimilars.

Learning Objectives

At the end of this CE activity, participants should be able to:
- Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
- Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
- Improve patient-provider communication patterns regarding appropriate use of biosimilars.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
- Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
- Explain how to improve patient-provider communication patterns regarding appropriate use of biosimilars.